Hyperfiltration-mediated Injury in the Remaining Kidney of a Transplant Donor.

Tarak Srivastava  
*Children's Mercy Hospital*

Sundaram Hariharan

Uri S. Alon  
*Children's Mercy Hospital*

Ellen T. McCarthy

Ram Sharma

*See next page for additional authors*

Follow this and additional works at: [https://scholarlyexchange.childrensmercy.org/papers](https://scholarlyexchange.childrensmercy.org/papers)

Part of the *Nephrology Commons*

**Recommended Citation**
[https://scholarlyexchange.childrensmercy.org/papers/1221](https://scholarlyexchange.childrensmercy.org/papers/1221)

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Creator(s)

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/1221
Hyperfiltration-mediated injury in the remaining kidney of a transplant donor

Tarak Srivastava, MD1,2, Sundaram Hariharan, MD3, Uri S. Alon, MD1, Ellen T. McCarthy, MD4, Ram Sharma, PhD2, Ashraf El-Meanawy, MD, PhD5, Virginia J. Savin, MD2,4, and Mukut Sharma, PhD2,4,6

1Section of Nephrology, Children’s Mercy Hospital and University of Missouri at Kansas City, Kansas City, MO, USA
2Renal Research, Research and Development, Kansas City VA Medical Center, Kansas City, MO, USA
3Department of Medicine and Surgery, Thomas E Starzl Transplant Institute, Pittsburgh, PA, USA
4Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA
5Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI, USA
6Midwest Biomedical Research Foundation, KCVA Medical Center, Kansas City, MO, USA

Abstract

Kidney donors face a small but definite risk of end-stage renal disease 15-30 years postdonation. The development of proteinuria, hypertension with gradual decrease in kidney function in the donor after surgical resection of 1 kidney has been attributed to hyperfiltration. Genetic variations, physiological adaptations, and co-morbidities exacerbate the hyperfiltration-induced loss of kidney function in the years following donation. A focus on glomerular hemodynamics and capillary pressure has led to the development of drugs that target the renin-angiotensin-aldosterone system (RAAS), but these agents yield mixed results in transplant recipients and donors. Recent work on glomerular biomechanical forces highlights the differential effects of tensile stress and fluid flow shear stress (FFSS) from hyperfiltration. Capillary wall stretch due to glomerular capillary pressure increases tensile stress on podocyte foot processes that cover the capillary. In parallel, increased flow of the ultrafiltrate due to single nephron glomerular filtration rate elevates FFSS on the podocyte cell body. While tensile stress invokes the RAAS, FFSS predominantly activates the COX2-PGE2-EP2 axis. Distinguishing these 2 mechanisms is critical, as current therapeutic approaches focus on the RAAS system. A better understanding of the biomechanical forces can...
lead to novel therapeutic agents to target FFSS through the COX2-PGE2-EP2 axis in hyperfiltration-mediated injury. We present an overview of several aspects of the risk to transplant donors and discuss the relevance of FFSS in podocyte injury, loss of glomerular barrier function leading to albuminuria and gradual loss of renal function, and potential therapeutic strategies to mitigate hyperfiltration-mediated injury to the remaining kidney.

Introduction

Living donor kidney transplantation compared to deceased donor transplantation has better short- and long-term outcomes in the recipient. Improved outcome is corollary to better kidney quality, shorter cold ischemia time, planned surgery, and shorter time on dialysis. In addition, limited availability of deceased donor organs and the ever-increasing need for kidney allografts for patients on dialysis have led transplant centers to encourage living donation. Since outcomes for recipients of kidneys from living donors are highly encouraging, living donor kidney transplantation is the treatment of choice. However, living donation carries a small but distinct risk to the kidney donor. Several factors may contribute to the risk of kidney disease in donors.

Some kidney donors will develop proteinuria, hypertension, decreased eGFR and End Stage Renal Disease (ESRD) from injury to the remaining kidney [1-7]. This injury is mainly attributed to hyperfiltration. Glomerular hyperfiltration in the remaining functional nephrons not only results from but also contributes to ongoing and repetitive glomerular injury. Hyperfiltration is recognized as a phenomenon of adaptive changes under both physiological and pathological conditions in the kidney. It involves changes in renal hemodynamics, glomerular hypertrophy, afferent arteriolar vasodilation, and/or efferent arteriolar constriction [8,9]. However, the exact mechanism by which hyperfiltration-induced injury is mediated remains unclear. Hyperfiltration is considered to be one of the underlying key mechanisms of renal damage in obesity, diabetes, and hypertension. These factors further exacerbate the deleterious effects of adaptive hyperfiltration on the structure-function integrity of the glomerulus. Development of 1 or more of these co-morbidities in kidney donors further aggravates the hyperfiltration-mediated injury. Affecting not only transplant donors, hyperfiltration also contributes to negative long-term outcomes in transplant recipients who are subjected to further injury through immunological and nonimmunological mechanisms.

Despite decades of familiarity with the concept of hyperfiltration, the mechanical and rheological aspects of hyperfiltration and their effects on glomerular structures such as podocytes remain unclear. The cellular and biological mechanism of hyperfiltration-mediated glomerular injury needs to be further investigated. In the following sections, we highlight the significance of hyperfiltration in living kidney donors and transplant recipients. We summarize hyperfiltration-induced morphological, hemodynamic and molecular changes observed in unilaterally nephrectomized rodent models. We also outline the results of recent in vitro and in vivo experiments to highlight the significance of hyperfiltration-associated biomechanical forces for a better understanding of the mechanism of hyperfiltration-mediated injury in donors.

Transplantation. Author manuscript; available in PMC 2019 October 01.
Glomerular hemodynamic changes in a single kidney

Glomerular filtration is a complex interplay of renal blood flow, ultrafiltration pressure ($P_{UF}$), and ultrafiltration coefficient ($K_f$), which is a product of area and hydraulic permeability ($L_p$) that determines the Single Nephron Glomerular Filtration Rate (SNGFR). SNGFR is derived from the following equation where $x$ represents the normalized length of the glomerular capillary with the afferent-end designated by 0 and the efferent-end by 1; $P$ and $\pi$ are the hydraulic and osmotic pressures, respectively, at distance $x$ along the capillary length; $\sigma$ is the reflection coefficient which has a range from 0 to 1 and; $K_f$.

$$SNGFR = K_f \int_0^1 [(P_g(x) - P_B) - \sigma(\pi_g(x) - \pi_B)] dx$$

Based on this equation, increased $K_f$ (dependent on $L_p$ and area) and/or $\Delta P$ (determined by $P_{GC}$ and $\Delta \pi$) would be the key determinants of increased SNGFR in hyperfiltration. These basic characteristics of glomerular hemodynamics are altered in a single kidney. Studies involving animal models and human subjects have relied on these parameters to determine changes in glomerular hemodynamics associated with kidney disease. Unilateral nephrectomy in rodents is an established approach to study the effects of hyperfiltration. Animal models provide the convenience of direct measurement of the components of the above equation and validation of the calculated SNGFR in humans. Celsi et al [10] showed that unilateral nephrectomy in 5-day old Sprague-Dawley rats resulted in an increased SNGFR and $P_{UF}$ in the early period (observed in 20-day old rats). An increase in glomerular area and a decrease in $L_p$ were additional changes observed at a later stage (60-day old rats). Further, Celsi et al [11] showed that high ultrafiltration pressure was not an absolute requirement for increasing SNGFR in unilaterally nephrectomized rats. The reported increase in SNGFR following unilateral nephrectomy ranges from 30%-36% in mice and 57%-86% in rats [10-14].

In the ALTOLD (Assessing Long Term Outcome in Living Kidney Donors) study, GFR, measured by plasma iohexol clearance, increased at a rate of $1.47 \pm 5.02$ ml/min/year in donors between 6 and 36 months compared to a decrease of $0.36 \pm 7.55$ ml/min/year ($p=0.005$) in controls on follow up [15]. The measured GFR continued to increase in kidney donors up to 36 months after donation, suggesting an ongoing increase in SNGFR following kidney donation.

In line with animal studies, Lenihan et al [16] found the mean single kidney GFR increased from 47 (predonation) to 64 (early postdonation) to 66 (late postdonation) ml/min/1.73 m$^2$ with a parallel increase in single kidney renal plasma flow of 235, 314, and 335 ml/min/1.73 m$^2$, renal cortical volume of 103, 131, and 139 cm$^3$, and calculated $K_f$ with a fixed glomerular transcapillary hydraulic pressure gradient ($\Delta P$) at 40 mmHg of 4.9, 7.1 and 7.0 ml/(min.mmHg) in 21 transplant donors. The study highlights the increase of SNGFR in transplant donors by ~40% with no or minimal increase in $\Delta P$ [16]. Thus, adaptive hyperfiltration in a single kidney results in a significant increase in SNGFR in humans (calculated) and in animal models (directly measured).
Long-term outcome for kidney donors

Living kidney donation is now a safe procedure following stringent donor screening. However, the long-term outcome for all kidney donors may not be as benign as previously reported [4,5]. Of historical note, Ronald Lee Herrick, the first living donor, in 1954, spent the last decade of his life on dialysis. As early as 1984, Hakim et al [17] identified proteinuria and hypertension without a significant increase in serum creatinine after long-term (≥10 years) follow up of 52 transplant donors. Timsit et al [18] showed ~30% decrease in eGFR following unilateral nephrectomy in 124 renal cancer patients and in 124 transplant donors. At 4 years, 16.2% and 5.3% of post-kidney resection renal cancer patients and transplant donors had an eGFR of <45 ml/min/1.73m². Ibrahim et al [19] reported eGFR <60, <45, and <30 ml/min/1.73m² in 35.6%, 10.9%, and 2.6%, respectively, as well as proteinuria in 6.1% of Caucasian donors within 10 years of kidney donation.

Differences between early and recent studies underscore the shift in thinking about the remaining kidney in the transplant donor. Earlier studies were based on small cohorts, use of general population as control, short duration follow-up, and serum creatinine as the main indicator of renal function. In contrast, recent reports are based on population risk models developed using large data sets. Mjøen et al [4] compared 1,901 transplant donors to 32,621 control healthy, eligible nondonors, and reported an adjusted hazard ratio of 11.38 for ESRD. The crude incidence of ESRD in these Norwegian donors was 302/million person-years compared to ~100/million person-years. Similarly, Muzaale et al [5] compared 96,217 transplant donors to 20,024 healthy nondonors. The estimated lifetime risk of ESRD was 90 per 10 000 donors and 14 per 10 000 healthy nondonors compared to 326 per 10 000 in the general US population. The Chronic Kidney Disease Prognosis Consortium reported that the risk of kidney disease at 15 years after donation is 3.5-5.3 times greater than that in the control population [7]. Li et al [20] reported a pooled rate of 1.1% for ESRD, 5.7% for proteinuria, and 20.9% for microalbuminuria at >10 years following donation. A meta-analysis comprising 52 studies with follow-up for 24 years reported a significant increase in relative risk for ESRD of 8.83 (95%CI 1.02-20.93) [1]. These findings have led to a closer examination of the statistical methods, selection of control cohorts, hereditary risk of ESRD between related donors, and other aspects of these studies. Overall, consensus appears to be emerging that at least some kidney donors may develop proteinuria, decreased eGFR and ESRD in the long-term, and that novel diagnostic and preventative approaches need to be developed.

Influence of age, gender and ethnicity on the remaining kidney in donors

Younger transplant donors (<35 years) of all ethnicities are at a higher risk of developing ESRD as they survive into old age [21,22]. In a population model, Kiberd [23] found the cumulative risk of ESRD in Caucasian male donors to increase by +1.01, +0.89, +0.67, and +0.50 at ages 20, 40, 50, and 60 years, respectively. A similar significant increase was seen in African American males, and in women of both ethnicities. Muzaale et al [5] reported a greater risk of ESRD among African American donors (50.8 per 10 000) compared to Hispanics (25.9 per 10 000) and Caucasians (22.7 per 10 000) as compared with nondonors. The calculated risk was 0.24% for African American men, 0.15% for African American women, and 0.08% for African American women.
women, 0.06% for Caucasian men, and 0.04% for Caucasian women [7]. Thus, young
African American men likely face the highest risk for ESRD in the years following kidney
donation [7,18,23]. Longer follow up of Caucasian male donors from Minnesota showed a
cumulative incidence of ESRD per 10,000 donors at 15, 30, and 40 years is 13.5, 68.7, and
78.7, respectively [19]. Massie et al [24] reported median (interquartile range) predicted risk
of ESRD of 1 (1-2), 6 (4-11), 16 (10-29), and 34 (20-59) cases per 10 000 donors at 5, 10,
15, and 20 years post-kidney donation, respectively. Matas et al [22] reported the cumulative
incidence of ESRD (95%CI) of 3.0 (0.0-8.9), 14.4 (2.9-28.5), 50.9 (22.8-83.3), 109.1
(61.0-159.3), and 381.0 (246.8-534.4) cases per 10 000 donors at 10, 15, 20, 30, and 40
years post-kidney donation, respectively. The mean interval to ESRD was 27.1 ± 9.8 years
[22]. These studies suggest that it takes ~15-30 years for hyperfiltration-mediated kidney
injury to become manifest in transplant donors.

Thus, adaptive hyperfiltration does not appear to be completely benign for all transplant
donors. A 50% reduction in total renal mass following kidney donation can result in ESRD
and a need for renal replacement therapy in the long-term. Quantitative approaches are being
increasingly employed to determine the risk of ESRD following kidney donation. These
prediction models are based on the data from donor follow up for 4-16 years but lack the
information on family history of ESRD that limits their value for predicting ESRD in
younger donors with and without a family history of ESRD. Such models will hopefully be
used to complement, but not replace, the comprehensive evaluation of a potential donor
[25-27]. These risk prediction models based on the work of Grams et al [7], Massie et al [24]
and Ibrahim et al [19] can be found at http://www.transplantmodels.com/esrdrisk/, http://
10.1681/ASN.2015091018/-/DCSupplemental, respectively, and are available for clinical
use.

The prevalence of ESRD or chronic kidney disease (CKD) Stage 5 in the general adult
population is only 0.1% compared to 0.2% for CKD Stage 4, 4.3% for CKD Stage 3, 3.0%
for CKD Stage 2, and 3.3% for CKD Stage 1 [28]. CKD Stage 5/ESRD represents only
0.2% of all adults with CKD [28]. Therefore, ESRD is only the tip of the iceberg that is
CKD. While recent studies clearly identify the risk of ESRD, donors with variable degrees
of CKD ranging from CKD Stage 2 to 4 still need to be adequately studied.

Amplification of hyperfiltration-mediated injury by co-morbid conditions in
donors

Genetic background, hypertension, diabetes, aging, obesity, low nephron endowment at
birth, smoking, and proteinuria have been implicated in the progression of CKD. The
following paragraphs summarize the significance of these co-morbid conditions in
hyperfiltration-mediated injury.

Apolipoprotein 1 (APOL1) and kidney donation

Several studies have observed that African American donors are at the highest risk for
developing CKD [21,23,24,29,30]. Apolipoprotein 1 (APOL1) gene variants (G1 and G2)
have been associated with poor outcomes in African-American [31]. APOL1 is a part of the innate immune response to *Trypanosoma brucei* infection [31,32]. The G1 and G2 variants make host APOL1 resistant to neutralization by serum resistance-associated protein of *Trypanosoma brucei* [32]. African-American with 2 copies of the APOL1 gene variants in contrast to those with 0 or only 1 copy were found to be at a greater risk of ESRD and, to have a more rapid decline in eGFR as reported by the African American Study of Kidney Disease and Hypertension (AASK), the Chronic Renal Insufficiency Cohort (CRIC) study, Coronary Artery Risk Development in Young Adults (CARDIA), Atherosclerosis Risk in Communities (ARIC), and the Chronic Kidney Disease in Children (CKiD) [33-36]. The ARIC study found large variability and substantial overlap in eGFR trajectory among Caucasians, African Americans with low-risk APOL1 status, and African Americans with high-risk APOL1 status, making it difficult to predict kidney disease [36].

Since the high-risk APOL1 genotype occurs in ~13% of the African American population [37,38] targeting potential kidney donors in this at-risk population has been proposed [39]. Doshi et al [40] examined the effect of the high-risk APOL1 genotype in African American living kidney donors, and found lower eGFR at baseline and follow up, and faster decline in eGFR compared to African American living donors with low-risk APOL1 genotype. In the same study they also compared donors matched to nondonors by APOL1 genotype, and found no difference in the rate of eGFR decline or an interaction by APOL1 status. Although the high-risk APOL1 genotype in living kidney donors was associated with a greater decline in eGFR, its trajectory was similar between donors and nondonors. Thus, the influence of the APOL1 genotype on the outcome for kidney donors is still under investigation. The question of whether African-Americans carrying high-risk APOL1 gene variants should be allowed to donate or not remains unresolved [41-43]. In addition to the high-risk genetic background, African-Americans have a relatively high prevalence of hypertension and diabetes, which would likely amplify the effect of hyperfiltration [29,30].

**Hypertension and kidney donation**

Matas et al [22] reported that for the majority of living donors ESRD occurred later in life with new onset diabetes and hypertension that change the slope of eGFR. This connection suggests an amplification of hyperfiltration-mediated injury by these co-morbidities. In a meta-analysis the weighted mean was found to be higher for systolic and diastolic blood pressure, 6 mm Hg [95%CI, 2 to 11 mm Hg] and 4 mm Hg [95%CI, 1 to 7 mm Hg], respectively [44]. A study linked to pharmacy claims reported that 17.8% of the donors had filled at least 1 antihypertensive medication within 5 years following donation [45]. In this study the use of antihypertensive medication was lower after kidney donation compared to the unscreened general population. Prevalence of hypertension following kidney donation is higher in African-American compared to Caucasian [45-48]. In a head-to-head comparison, African-American donors were found to have a higher incidence of hypertension compared to healthy non-donor African-American (40.8% vs. 17.9%, RR 2.4, 95%CI 1.7-3.4) [48]. In comparison with healthy controls, living donors have higher rates of hypertension (16.3% vs. 11.9%, HR 1.4, 95%CI 1.2-1.7) [49]. Thus, kidney donation may accelerate the risk of progression of hypertension in the donor, and more so in African-Americans.
The loss of normal nocturnal fall in BP during the sleep state (or nondipping) on ambulatory blood pressure monitoring (ABPM) has been shown to be a risk factor for cardiovascular events, but only a small number of studies reporting ABPM in living donors are available. Although the blood pressure on ABPM was not elevated after donation, 39.4% of living kidney donors were found to be nondippers [50]. In a short follow up for 6-12 months, 2 studies found no significant difference in adverse outcomes among donors who were nondippers at baseline [51,52]. Another study found similar systolic and diastolic BP measurements, and nondipping status between donors and controls at 10 years following donation [53]. The EARNEST study is an ongoing prospective, multicenter, longitudinal, parallel group study of 440 living kidney donors and 440 healthy controls involving measurement of arterial stiffness, office blood pressure, ABPM, and a series of biomarkers for cardiovascular and bone mineral disease at baseline and at 12 months [54]. Results of this study may provide further information on blood pressure changes and cardiovascular outcomes in donors.

Diabetes and kidney donation

Diabetes is the leading cause of ESRD. In diabetic kidney disease, a subject may progress through the classical 5 stages: (1) Early functional phase with reversible glomerular hyperfiltration, (2) Normal GFR and normal urine albumin excretion (< 30 mg/day), (3) Incipient nephropathy, defined by normal GFR and microalbuminuria (30–300 mg/day), (4) Macroalbuminuria (>300 mg/day), and (5) ESRD [55]. Approximately 5-10 years following the onset of diabetes, 20 - 40% patients develop microalbuminuria. Of these patients 80-90% progress to more advanced stages. After 10-20 years, 20-40% of patients develop macroalbuminuria, and about half of them progress to ESRD within 5 years [55]. The United Kingdom Prospective Diabetes Study (UKPDS64) reported that following the diagnosis of diabetes, microalbuminuria occurred at 2.0% per year, progression from microalbuminuria to macroalbuminuria at 2.8% per year, and progression from macroalbuminuria to elevated plasma creatinine or ESRD at 2.3% per year [56]. At 10 years following the diagnosis of diabetes, prevalence rates were at 24.9% for microalbuminuria, 5.3% for macroalbuminuria, and 0.8% for elevated plasma creatinine or ESRD [56]. Thus, the timescale for development of diabetic nephropathy is very similar to those of kidney disease in kidney donors.

Hyperfiltration is a maladaptive response in diabetes which predisposes the glomerulus to irreversible damage of nephrons and development of progressive renal disease [57]. The initial phase of diabetic kidney disease is characterized by glomerular hyperfiltration with an absolute increase in whole-kidney GFR [58]. GFR increases by 10-67% in Type 1 diabetes and 6-73% in Type 2 diabetes [58-60]. Increased SNGFR is believed to maintain whole-kidney filtration within the normal range in diabetic subjects to compensate for reduced nephron number (renal mass) and/or as a response to metabolic and (neuro)hormonal stimuli from diabetes itself [58]. This elevated SNGFR then contributes to the decline in renal function [58]. A de novo development of diabetes and hypertension following kidney donation increases the risk of proteinuria by ~4-fold, and for ESRD by ~2-fold [7].
Aging and kidney donation

In Caucasians, but not in African Americans, the risk for lower eGFR increases with age at donation [6]. Denic et al [61] showed a decrease in nonsclerotic (functional) nephrons and cortical volume with age in normal healthy adults. Older donors (>55 years) compared to younger donors (<45 years) have lower GFR, decreased renal cortical volume, and lower whole kidney $K_f$ attributed to a decrease in the number of functional nephrons prior to donation [62]. Thus, an age-associated decrease in the number of functional nephrons would likely exacerbate hyperfiltration in the remaining kidney in the donor as well as in the recipient.

Obesity and kidney donation

Several studies have found that obesity increases the risk of adverse outcomes in kidney donors [6,7,24,29,30]. The estimated risk of ESRD at 20 years postdonation is reportedly 93.9 per 10 000 in obese (BMI >30 kg/m$^2$) compared to 39.7 per 10 000 in nonobese donors [63]. Ibrahim et al [19] showed that for every 1 unit increase in BMI there is an associated 3%-10% greater risk for decreased eGFR and increased proteinuria. In donors with BMI >30 kg/m$^2$ for every 5 kg/m$^2$, Grams et al [7] found that the risk of ESRD increased by 16% (HR 1.16, 95%CI 1.04-1.29), while Massie et al [24] reported an increase of 61% (HR 1.61, 95%CI 1.29-2.00). Chagnac et al [64] showed that obese (BMI >38 kg/m$^2$) nondiabetic individuals have increased GFR, renal plasma flow, and urinary albumin excretion rate. Dextran-sieving profiles suggested that increased SNGFR (ie, hyperfiltration) in obese individuals was due to increased ΔP from dilatation of the afferent arteriole.

Low nephron number and kidney donation

The significance of low nephron endowment in the progression of CKD, hypertension, and cardiovascular outcomes for both adults and children has been highlighted over the past decade [65-79]. Thus, low nephron endowment, loss of nephrons with age, hypertension, diabetes, and obesity would further amplify the hyperfiltration-associated glomerular changes in living donors. While one cannot control aging, sex, ethnicity, and genetic background, careful monitoring to control postdonation co-morbidities (eg, excessive weight, hypertension and diabetes), and guidance to avoid smoking and nephrotoxic drugs are within the physician’s reach.

Relevance of hyperfiltration-mediated injury in kidney transplant recipients

Recent decades have witnessed significant improvements in the short-term outcomes for recipients of kidney transplantation, but progress toward improving long-term outcomes remains a challenge. Unfortunately, almost half of the allografts are lost within 10 years posttransplantation [80]. Interstitial fibrosis with tubular atrophy (previously known as chronic allograft nephropathy) and death while the graft is functioning are the 2 major causes of graft loss in recipients that have remained unchanged [81,82].

The transplanted kidney in the recipient is also exposed to hyperfiltration-mediated injury. Additionally, the transplanted kidney in the recipient, is also exposed to a host of adverse conditions, including immunological and nonimmunological injury such as acute and
chronic rejection, recurrence of the disease, acute and chronic infections, ischemia-reperfusion injury, drug toxicity, renal artery stenosis, urinary tract obstruction, hypertension, diabetes, donor APOL1 genotype, etc. Immunological and nonimmunological injuries further accelerate the progression of CKD in transplant recipients compared to donors. We believe that the development of therapies to mitigate hyperfiltration-mediated injury will benefit the transplant recipients as well as donors.

African-American transplant recipients with high-risk APOL1 genotype compared to low-risk APOL1 genotype showed no difference in allograft survival [83]. On the other hand, Reeves-Daniel et al [84] reported shorter allograft survival in recipients from deceased donor kidneys with high-risk APOL1 genotype. This observation has been validated by large cohort studies that reported shorter renal allograft survival and higher follow-up serum creatinine concentrations in recipients of kidneys from donors with high-risk APOL1 genotype compared to low-risk APOL1 genotype [85,86].

**Old versus newer paradigms for hyperfiltration-mediated injury**

Early work by Brenner and colleagues used the 5/6 nephrectomy rat model to demonstrate a strong link between increased ΔP or PGC and kidney injury, and to highlight the importance of hyperfiltration-mediated injury [8,9]. Subsequent seminal work from Brenner and colleagues led to characterization of the renin-angiotensin-aldosterone system (RAAS). With these ground-breaking findings, several RAAS blockers were developed to mitigate hyperfiltration-mediated kidney injury in humans [8,9]. As mentioned earlier, most research on adaptive hyperfiltration to date has focused on glomerular pressure and renal hemodynamics. Such singular focus on glomerular capillary pressure has also uncovered the unexplained role of several factors that contribute to hyperfiltration-mediated glomerular injury leading to CKD.

With the benefit of hindsight gained from previous work by others on hemodynamic parameters, our group and others in the field are reexamining hyperfiltration. This new paradigm explains the effect of hyperfiltration in terms of glomerular biomechanical forces, namely tensile stress and fluid flow shear stress (FFSS) on the podocyte [87-92]. We propose that renal injury in transplant donors primarily stems from increased biomechanical forces. A better understanding of these biomechanical forces corresponding to persistent hyperfiltration will likely lead to identification of novel therapeutic targets and drug development that would complement currently used RAAS blockers in mitigating hyperfiltration-mediated injury.

**Biomechanical forces associated with glomerular ultrafiltration**

Glomerular filtration barrier, the site of plasma filtration, is constituted by glomerular capillary endothelial cells, basement membrane (GBM), and podocytes (visceral epithelial cells). Mesangial cells also contribute to the barrier function by stabilizing the glomerular structure. Structural and functional integrity of all components of the barrier are essential but podocytes are distinct in several ways. Podocytes are large cell bodies within Bowman’s space covering the capillary with foot processes that form slit junctions by interdigitating
with foot processes from other podocytes. Slit junctions are critical for a size-based filtration of plasma components. However, in contrast to mesangial and endothelial cells, podocytes are terminally differentiated cells with low mitotic potential. Changes in the capillary pressure and the flow of the glomerular ultrafiltrate subject podocytes to pressure and flow-associated biomechanical forces that may result in their detachment [90-93]. These rheological factors and the inability to replace the lost cells render podocytes the most vulnerable component of the glomerular filtration barrier vis-à-vis mesangial and endothelial cells.

The passage of blood through the capillary and the flow of the ultrafiltrate along the podocyte surface can be explored using principles of fluid mechanics. Blood flow through capillary loops generates force radially at 90° to the direction of flow, causing the capillary wall to stretch and dilate which, in turn, radiates the force to podocyte foot processes attached to the GBM on the outer aspect of the capillary (Figure 1). Glomerular capillary pressure within the vascular compartment is the major determinant of tensile stress exerted over the basolateral aspect of podocytes [90,94]. The stretch on podocyte foot processes attached to the GBM results in tensile stress on podocytes. Kriz and Lemley [87] have suggested that the burden for counteracting transmural pressure gradients (or tensile stress) falls largely on the GBM, which can create significant elastic counterforce to balance the effects of increased transmural pressure. In vitro methods to study tensile stress are based on techniques to induce elongation or compression of cells. The most common method involves growing podocytes on a flexible membrane of specially constructed cell culture dishes. Negative pressure (vacuum) is applied to create a cyclical or sustained stretch to adherent cells on the flexible membrane. The stretch can be applied in 1 or 2 dimensions, resulting in uniaxial or biaxial stress. Other variables in these experiments include the (a) frequency (cycles/second, Hz), (b) magnitude (percent change), (c) pattern of application (square-wave or sine-wave), and (d) the duration of stretch. Additional methods to study axial stress include application of hydrostatic force, hypo-osmotic stretch, or magnetic pull [95-97].

Ultrafiltrate flow generates another biomechanical force, namely FFSS associated with hyperfiltration that has direct consequences for the structural integrity of podocytes [87,94,98,99]. We and others have shown that an increase in FFSS alters podocyte structure that changes glomerular filtration barrier function leading to an increase in urinary protein excretion [87,98]. FFSS is a measure of the frictional force from a fluid acting on a body in the path of that fluid. In humans, the flow of 180 L/day of ultrafiltrate over the cell body and major processes exerts FFSS on podocytes (Figure 1) [90,99]. The major determinant of FFSS over the podocytes is SNGFR [90,92]. In vitro methods to study fluid flow shear stress (τ) use technique(s) for controlled flow of a fluid column over cells. A commonly used method involves fluid flow over the cells grown on glass slides. In these experiments the height (h), width (w), and viscosity (η) of the fluid column (eg, cell culture medium) are constant [98,100]. The rate of flow (q) of the fluid column determines the magnitude of FFSS on the cell given by the equation for parallel plate geometry, \( \tau = \frac{6\eta q}{wh^2} \). Fluid column can be patterned as laminar, pulsatile, or oscillating. Another method to apply FFSS is by rotational flow of fluid on an orbital shaker [101]. FFSS at the bottom of the dish is
calculated using the equation \( \tau_{\text{max}} = \alpha \rho \eta (2\pi f)^3 \frac{1}{2} \), where \( \alpha \) is the radius of orbit rotation, \( \rho \) is the density of the fluid medium, \( \eta \) is the viscosity of the fluid medium, and \( f \) is the frequency of rotations per second.

Hyperfiltration increases tensile stress as well as FFSS on podocytes within the glomerulus [98-104]. The engineering aspects of stresses and strains involved in generation of biomechanical forces on podocytes within the glomerulus during glomerular filtration have been reviewed in detail by Srivastava et al [91]. Our findings (vide infra) as well as those reported by Kriz and Lemley [88] suggest that FFSS is the main detrimental biomechanical force in glomerular injury and plays a major role in detaching podocytes from the glomerular basement membrane. In contrast to tensile stress, FFSS directly impacts podocyte structural integrity and stability, and contributes to podocyte loss. Therefore, study of the effect(s) of biomechanical forces on podocytes appears to be the next logical step to advance our understanding of hyperfiltration-mediated glomerular injury.

**Activation of the Renin-Angiotensin-Aldosterone System (RAAS) by tensile stress and of the Cyclooxygenase 2 - Prostaglandin E2 - EP2 Receptor (COX2-PGE2-EP2) axis by fluid flow shear stress**

Studies addressing the role of glomerular biomechanical forces suggest that tensile stress activates the RAAS whereas FFSS engages the COX2-PGE2-EP2 axis [98,104]. Capillary pressure-related changes and the activation of RAAS have been investigated for over half a century [105-112]. Briefly, podocytes express all components of the RAAS as well as receptors for angiotensin II [104]. Tensile stress results in increased secretion of angiotensin II, influx of Ca\(^{2+}\), up-regulation of the angiotensin-II receptor (AT1R), COX2, EP4, osteopontin, and activation of p38 MAPK, ERK1/2 and JNK [94,104,113,114]. Characterization of the RAAS led to development of several RAAS blockers that include angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists, and direct renin inhibitors. ACEI and ARB, alone or in combination, have been shown to delay the progression of CKD/ESRD in diabetic nephropathy [115-117]. Subsequently RAAS blockers were shown to be effective in delaying the progression of CKD/ESRD in nondiabetic proteinuric kidney diseases [118-121]. These beneficial effects of RAAS blockers have been attributed to reduced hyperfiltration-mediated kidney injury. However, RAAS blockers interfere with the autoregulation of RBF and GFR, especially in patients with bilateral renal artery stenosis or those with stenosis in a solitary kidney requiring angiotensin II to maintain renal perfusion [122,123]. Thus, physicians hesitate using RAAS blockers in patients with solitary functioning kidney [124]. Compelling data on the efficacy of RAAS blockers in nontransplant populations led to studies of transplant recipients. These studies do not support the use of RAAS blockers for improving clinical outcomes in transplant recipients and suggest that these drugs may, at times, be detrimental to graft function and survival [124-128]. In view of the pharmacological effects of RAAS blockers on glomerular hemodynamics, the role of these drugs in controlling proteinuria and hypertension in transplant donors and recipients continues to be controversial [129-132]. A recent meta-
analysis could neither support nor refute the use of RAAS blockers in transplant recipients [133]. Accumulating evidence shows beneficial effects of RAAS blockers in many proteinuric CKD patients, but not in subjects with sickle cell disease [134,135], autosomal dominant polycystic kidney disease [136,137], or congenital anomalies of the kidney and urinary tract [138].

Research on the role of FFSS is nascent but has yielded promising results that encourage a search for additional molecular targets to treat hyperfiltration-induced renal injury. COX1 and 2 activities on arachidonic acid generate several metabolites with prostaglandin E2 (PGE2) as a major prostaglandin. PGE2 is a ligand of 4 transmembrane G-protein coupled receptors, namely EP1-EP4. We have shown that podocytes express EP2 and EP4 [102]. PGE2-EP receptor complexes can activate several signaling pathways [139]. Our laboratory has led the efforts to explore the molecular mediators of changes in podocytes caused by increased FFSS. During the past decade we have found that podocytes exposed to FFSS in vitro and in vivo show upregulation of COX-2 but not COX-1, induction of PGE2 receptor EP2 but not EP4, elevated PGE2 levels, and derangement of the actin cytoskeleton. Additionally, glomeruli exposed to FFSS showed an increase in glomerular albumin permeability (P Alb) [98,100,102,103]. Indomethacin blocked each of these effects of FFSS [98,100]. Thus, the activity of the COX2-PGE2-EP2 axis in podocytes and glomeruli was upregulated following an increase in FFSS in both cell and animal studies [98,100,102]. The relevance of the COX2-PGE2-EP2 axis is further supported by studies using animal models of hyperfiltration of 5/6 nephrectomy, high dietary protein, and diabetes which show increased renal COX-2 expression, renal PGE2 synthesis, and urinary PGE2 [140-147]. We recently reported that FFSS on podocytes recruits the Akt-GSK3β-β-catenin, ERK1/2, and p38MAPK signaling pathways, but not the cAMP-PKA pathway [139]. Activation of the COX2-PGE2-EP2 axis through membrane-localized EP2 receptor and its link to genome activation in the nucleus through transcriptional factors is a subject of ongoing studies.

Each of these and other mechanisms may be important in how podocytes respond to FFSS and tensile stress. The known significance of tensile stress and the RAAS is the basis for using RAAS blockers. Our work suggests that research on FFSS may lead to additional targets such as EP2 and/or downstream signaling molecules [139]. EP2 receptor activation has been found to be deleterious in chronic inflammatory neurodegenerative diseases and colon cancer [148,149]. Currently under development, EP2 antagonists to treat these diseases will also be relevant for kidney donors. Thus, studies on biomechanical forces within the glomerulus will likely identify novel non-RAAS pathways activated in response to hyperfiltration. We postulate that modulating EP2 receptor would be a valuable target to mitigate hyperfiltration-mediated injury, in addition to the known RAAS blockers in kidney donors.

Hyperfiltration continuum model in progression of chronic kidney injury in donors

In most CKD, a gradual loss of functional nephrons over time leads to persistent hyperfiltration in the remaining glomeruli. Adaptive changes initially appear in the form of
increased SNGFR due to greater renal blood flow and $K_f$. Animal studies show that hyperfiltration is associated with increased SNGFR due to higher $K_f$ and blood flow during the initial phase followed by a gradual increase in $\Delta P$ or $P_{GC}$ in the later period [9-14,112]. Similarly, a gradual loss of functional nephrons in CKD results in a proportional intensification of ongoing hyperfiltration. In both animal and human studies as discussed earlier, an early increase in SNGFR is followed by an increase in $P_{GC}$ as the kidney suffers progressive loss of function from mild to moderate and severe. Over time, the loss of functional nephrons results in glomerular hypertension from increased $P_{GC}$. We conceptualize a rapid decline in GFR in the later stages of CKD from acceleration in hyperfiltration-mediated injury with continuing and cumulative loss of functional nephrons. This association between increased $P_{GC}$, ie, tensile stress and proteinuria, has been recognized since Brenner’s findings and addressed in animal and clinical studies with RAAS blockers [8,9]. However, the role of increased SNGFR due to ultrafiltrate flow, ie, FFSS, was not a part of earlier investigations on hyperfiltration-mediated glomerular injury.

We have developed a model to outline the significance of FFSS and tensile stress. This model emphasizes that a gradual decline in GFR from 100% to 0% and persistent hyperfiltration, increased FFSS from SNGFR, and increased tensile stress from $P_{GC}$ all play important roles in causing progressive damage to podocytes and loss of glomerular function. As shown in Figure 2, hyperfiltration-mediated changes may be conceptualized as a continuum where both FFSS and tensile stress contribute sequentially and additively to podocyte injury. In Figure 2, the arrow (top) indicates the average reported GFR in the early period following kidney donation. The study by Lenihan et al [16] highlighted that SNGFR in transplant donors increased by ~40% with none-to-minimal increase in $\Delta P$. Timsit et al [18] found ~30% decrease in eGFR following unilateral nephrectomy in transplant donors and renal cancer. Thus, an increase in SNGFR corresponds to higher FFSS over podocytes and precedes the rise in $P_{GC}$ (and tensile stress) in this continuum (see lower half of Figure 2). We have observed a 1.5- to 2-fold increase in FFSS following unilateral nephrectomy in animals and, based on available human studies, hypothesize an increase in FFSS in a kidney donor [103].

However, early molecular, biochemical, and signaling changes in podocytes prior to an increase in $P_{GC}$ are not known. Figure 2 also highlights the need for research to investigate the early response in podocytes when SNGFR rises without an increase in $P_{GC}$. In this regard, the COX2-PGE2-EP2 axis is a candidate pathway for further studies. We propose that the COX2-PGE2-EP2 axis and components of the RAAS are relevant in the early and late stages of the hyperfiltration continuum, respectively. Outlining the slow progression of CKD enables us to model hyperfiltration-associated changes with the inclusion of potential contributing factors that amplify hyperfiltration, such as obesity, hypertension, diabetes, etc. and their temporal entry into the hyperfiltration continuum. Conceptualizing hyperfiltration as a continuum rather than a distinct event also allows inclusion of overlapping adaptive and maladaptive changes that, in turn, generate cellular responses within the glomerulus (Figure 2). The gradual nature of glomerular changes becomes apparent in the proposed model of hyperfiltration as a continuum and provides an opportunity for innovative intervention for protecting the remaining kidney in transplant donors. Thus, the key to improving outcomes in kidney donors lies not only in understanding the mechanistic basis, but also in identifying...
new targets for therapeutic interventions in hyperfiltration-mediated glomerular injury. This model highlights the opportunity to explore new targets by including changes in glomerular biomechanical forces occurring over the continuum.

Summary

In the foregoing text we sought to connect multiple topics related to epidemiology, clinical information, physiology, animal models, cell biology and molecular signaling in hyperfiltration-mediated injury resulting from loss of 1 kidney in living donors. Each of these sections could be explored in greater detail but we aimed at highlighting the diverse factors that influence the outcome following kidney donation. Further, accumulating data on living donors is just beginning to shed light on the long-term functional changes in the remaining kidney. Hyperfiltration-mediated injury ran as a common thread linking subsections of this article to advance the recent work on biomechanical forces. We thus bring attention to the significance of biomechanical forces in hyperfiltration-mediated injury in donors in this overview. The specific role of biomechanical forces, ie, tensile stress and FFSS, needs to be further validated in transplant donors. The progression of CKD/ESRD following kidney donation is also influenced by ethnicity (APOL1 gene variants), age, hypertension, obesity, smoking, etc. Whether the known risk factors such as obesity, hypertension, diabetes, etc. would amplify or simply add to the effect of biomechanical forces, needs to be further explored. The new paradigm based on biomechanical forces to understand the mechanism of hyperfiltration-mediated injury identifies COX2-PGE2-EP2 axis as a potential target for intervention to complement the currently used RAAS blockers in mitigating injury. It would be too early to conclude but EP2 receptor antagonists currently being investigated in clinical studies raise the possibility of intervention for kidney donors at greater risk for progression of CKD/ESRD.

Living kidney donation is an indispensable option for patients with ESRD. However, donors with the remaining kidney are at a small but distinct risk for developing ESRD themselves. Identifying the subset of donors at greater risk of CKD (a) before and (b) after transplantation will help minimize the risk to donors. In this regard, low nephron endowment at birth sets the foundation for nephron deficiency (or inadequacy) through kidney donation [75-79]. The impact of nephron mass reduction following donation would be amplified in those with unidentified low nephron number prior to kidney donation. Technological advances have made it possible to estimate nephron number in animals using MRI [150]. Progress in imaging techniques will provide sophisticated information on the status of a donor kidney prior to transplantation to exclude candidates with low nephron endowment. Due to technical limitations, this method is not yet ready for human use. In addition, the usefulness of prescreening African American donors for high risk APOL1 gene variants predonation and of withholding donation is under discussion [41,43]. Biomarkers that are associated with progression of CKD may be useful in identifying donors at increased risk. Urinary epidermal growth factor has recently been identified as a biomarker to identify patients at greater risk of progression while in early stages of CKD [151]. In a small group of children with solitary functioning kidney, we have found an increase in urinary PGE2 and a decrease in PGI2 [90]. The usefulness of these novel imaging techniques and biomarkers needs to be validated in large transplant donor cohorts.
As the number of living donors is consistently increasing by ~5,500 each year, there is growing recognition that kidney donation exposes the donor to a small but definite risk for CKD. The foregoing discussion in this overview has outlined the risk(s) to the remaining kidney of living transplant donors and transplant recipients. Inability to successfully treat such patients underscores the limitations of current treatment regimens. Thus, in addition to mandating a stringent follow up, it would be prudent to invest resources to advance our understanding of the mechanistic basis of injury from adaptive hyperfiltration, and to develop tools to identify donors at risk before and after donation. Further research to understand the mechanism(s) of injury, to identify novel targets, and to develop the next generation of therapeutics to preserve kidney function in transplant donors (Figure 3) will encourage and support kidney donation. A treatment strategy to mitigate FFSS-mediated injury will build on existing knowledge supported by clear scientific rationale for optimizing long-term kidney function in donors.

Acknowledgments

We gratefully acknowledge the contribution of many investigators whose work could not be cited here. Space limits do not permit inclusion of references to all the work that helped our progress with the ideas discussed in this article.

Funding

This work was supported by NIDDK R01DK107490 (Srivastava, Sharma), the Department of Veterans Affairs, the Veterans Health Administration, Office of Research and Development, VA BX001037 (Savin, Sharma), DK 1RO1 DK064969 (McCarty, Sharma), the Sam and Helen Kaplan Research Fund in Pediatric Nephrology (Alon, Srivastava), and the Midwest Biomedical Research Foundation (Savin, Sharma).

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD</td>
<td>Chronic Kidney Disease</td>
</tr>
<tr>
<td>COX2</td>
<td>Cyclooxygenase 2 Enzyme</td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated Glomerular Filtration Rate</td>
</tr>
<tr>
<td>EP$_2$</td>
<td>Prostanoid Receptor EP$_2$</td>
</tr>
<tr>
<td>EP$_4$</td>
<td>Prostanoid Receptor EP$_4$</td>
</tr>
<tr>
<td>ESRD</td>
<td>End-Stage Renal Disease</td>
</tr>
<tr>
<td>FFSS</td>
<td>Fluid Flow Shear Stress</td>
</tr>
<tr>
<td>K$_f$</td>
<td>Glomerular ultrafiltration coefficient</td>
</tr>
<tr>
<td>L$_p$</td>
<td>Hydraulic permeability</td>
</tr>
<tr>
<td>P$_{alb}$</td>
<td>Glomerular albumin permeability</td>
</tr>
<tr>
<td>P$_{GC}$</td>
<td>Glomerular capillary pressure</td>
</tr>
<tr>
<td>P$_{G_2E}$</td>
<td>Prostaglandin E$_2$</td>
</tr>
<tr>
<td>P$_{UF}$</td>
<td>Glomerular ultrafiltration pressure</td>
</tr>
</tbody>
</table>
RAAS  Renin-Angiotensin-Aldosterone System
SNGFR  Single Nephron Glomerular Filtration Rate
Δπ  Difference in osmotic pressure

References


Figure 1.
The large podocyte cell body (CB) localizes in the glomerular urinary space anchored to the capillary surface through major processes (MP) that branch into foot processes (FP) to cover the glomerular basement membrane (GBM) of the capillary wall (shown by black dashed circle). Foot processes experience the stretch caused by glomerular capillary pressure ($P_{GC}$, straight line arrows), resulting in tensile stress on the podocyte. The ultrafiltrate flowing over the cell body and major processes of the podocyte exerts fluid flow shear stress (FFSS) on podocytes (shown by blue curved arrows). Early hyperfiltration in the remaining kidney of donors results in increased FFSS on podocytes from increased single nephron glomerular filtration rate. These changes are later exacerbated by increased tensile stress on podocytes from a rise in glomerular capillary pressure ($P_{GC}$).
Hyperfiltration-mediated hemodynamic changes may be conceptualized as a continuum. In most kidney diseases, a gradual loss of functional nephrons over time leads to hyperfiltration in the remaining glomeruli. Adaptive changes initially appear in the form of increased single nephron glomerular filtration rate (SNGFR) from changes in renal blood flow and ultrafiltration coefficient ($K_f$). Over time, progressive loss of functional nephrons results in glomerular hypertension from increased glomerular capillary pressure ($P_{GC}$). We theorize that in the later stages of CKD with continuing loss of functional nephrons there will be a more rapid decline in GFR from acceleration in hyperfiltration-mediated injury. We propose that the cyclooxygenase 2 enzyme - prostaglandin E$_2$ - prostanoid receptor EP$_2$ (COX2-PGE$_2$-EP$_2$) axis and components of the renin-angiotensin-aldosterone system (RAAS) are relevant in the early and late stages of the hyperfiltration continuum, respectively (see text for details). The red arrow marks the average reported GFR in the early period following kidney donation. Early molecular, biochemical, and signaling changes in the podocyte prior to an elevation of $P_{GC}$ are not known. Slow progression of the disease provides an opportunity for innovative intervention to protect the remaining kidney of donors.
Figure 3.
Outline of a conceptual model of hyperfiltration-mediated injury in the remaining kidney in transplant donors. The 2 biomechanical forces, namely fluid flow shear stress (FFSS) caused by single nephron glomerular filtration rate (SNGFR) and tensile stress caused by glomerular capillary pressure ($P_{GC}$), mediate different pathways that can be potentially targeted by drug therapy (shown by lightning arrow). These forces have been shown to cause damage to the glomerular filtration barrier, leading to proteinuria and nephron loss. This begets additional nephron loss through further increasing the biomechanical forces, thus setting up a spiraling cascade.